Mike McMullen
President and Chief Executive Officer at Agilent Technologies
Thanks, Parmeet, and thanks everyone for joining our call today. In the third quarter, we once again demonstrated the strength of our diversified business and the unstoppable One Agilent team. We delivered an excellent quarter, significantly exceeding our revenue and earnings expectations. Revenues of $1.72 billion are up 13% core. This is on top of 21% core growth in Q3 of 2021.
Third quarter operating margins are 27.5%. Operating margins continue to expand and are up 150 basis points from last year. Earnings per share of $1.34, up 22%. Our strong results in Q3, coupled with orders continue to outpace revenues highlight the ongoing strength of our diversified business. The momentum in our business continues, and we are once again raising our outlook for the year.
Let's take a close look at our Q3 results. From an end market perspective, our results were once again led by strength in our two largest markets; Pharma and Chemical & Energy. Our largest market, Pharma grew 16% versus 27% a year ago. Within Pharma, both the Biopharma and Small Molecule segments grew double-digits. The momentum in our C&E market segment continues with Q3 growth of 22%. This is on top of 23% growth a year ago. The C&E market is being fueled by demand in chemicals along with strong secular demand and ongoing investment within the Advanced Materials space.
We're also very pleased to achieve double-digit growth in the Food and Environmental and Forensic markets, with both markets growing 11%. In our last call, I shared I believe that the business impact for the Shanghai COVID-19 lockdown would be transitory. I also expressed that we remain confident about the ongoing strength of our business in China, in Q3, that China can deliver 29% growth. These stellar results were driven by continued strong end-market demand, coupled with the fast and expect recovery production and shipment activity following the end of the Shanghai area lockdown.
We're also very pleased with these results, which highlights the customer focus, drive, and outstanding execution of the Agilent China team. Strength in Americas continued as we posted another quarter of double-digit growth on top of 32% growth last year. Our European business grew 6% against the 23% last year, despite a two-point headwind for the curtailment of our operations in Russia. In terms of business unit performance, the Life Sciences and Applied Markets revenues of $1.02 billion, up 18% on a core basis.
Growth was broad-based, with continued strong demand for our LC & LC/MS offerings, where we posted high-20s growth. Our Spectroscopy business grew low-30s, driven by strength in Advanced Materials market. Chemistries and Consumables, Cell Analysis and our GC business, each delivered double-digit growth in the quarter. LSAG's end market growth is broad-based with particular strength in the Pharma and Chemical & Energy markets. Our Pharma results were driven by strength in the Biopharma segment, which grew more than 20%. We had an excellent show in the recent ASMS Conference introducing several important LC/MS and GC/MS Instruments and Biopharma Workflow Solutions.
These innovative and intelligent LC/MS and GC/MS systems have been designed to make the lives of our customers easier. The build in instrument intelligence and a higher level instrument diagnostics helped maximize system up-time and improve lab productivity by allowing operators to focus on their analysis rather than on their instruments. In addition, we introduced an industry-first hydro-inert source for GC-Single Quad and GC-Triple Quad instruments, enabling customers to seamlessly migrate from helium as a supplier gas to lower cost hydrogen.
And rounding up the list of new products announced at ASMS, we introduced the MassHunter BioConfirm 12.0 software, an integrated compliant workflow targeted at the fast-growing oligo-based therapies development market. These new products have already been well received by customers and represent the latest addition to Agilent history of leadership and mass spectrometry. Our LSAG business also won some important awards during the quarter, included the 6560C Ion Mobility LC/Q-TOF System winning the Scientist Choice Award for Best New Spectroscopy Product. Earlier this month, we also strengthened and broadened our Advanced Materials and Biopharma portfolio with the acquisition of PSS, Polymer Standards Service, a leader in polymer characterization.
We're extremely pleased to welcome the PSS Team and their technology to the Agilent family. The Agilent CrossLab Group posted services revenue of $359 million. This is up 10% core. We do a 10% core even as lab activity continues to ramp in China. Growth in services was again broad-based across services contracts, preventive maintenance, compliance, education and informatic enterprise services. Strong instrument placement and increased connect rate continue to be a driver of service business as customers continue to see value in our ACG offerings. Another critical important factor on our results is the scale and execution capability of Agilent's world-class global service delivery organization and sort of our customers meet their needs. Agilent seen as the trusted Company to work with among our global customers.
The Diagnostics and Genomics Group delivered revenue of $340 million, up 3% core. This is versus I compare a 37% growth last year. The solid results in our clinical cancer testing and NGS businesses were partially offset by COVID testing headwinds in a qPCR portfolio. In addition, the DGG business in China continues to ramp from the COVID-related shutdowns there. NASD revenues were up modestly in line with expectations. As we noted last quarter, Q3 included the impact of planned shutdown of our oligo manufacturing line in Frederick, Colorado. The shutdown of Frederick was for both routine maintenance and development of key elements of our Train B. Our new manufacturing line have increased our capacity, $150 million plus when fully ramped.
While we continue to make good progress on the construction of Train B, we have seen some supply chain related delays and are now targeting mid-year 2023 go-live, a slight delay. We see continued strong demand for oligo-based therapies as the number of approved drugs continues to increase and the pipeline of drugs in development are targeting these states with larger patient populations. We are more confident than ever in the long-term trajectory of the market and our business.
In addition to these highlights, I'd like to also point the recent release of Agilent's 2021 ESG Report. While we've always published our progress and sustainability and addressing societal needs, this year we've taken our approach to the next level. We address these issues in a new format that for the first time that looks specifically at our progress in the areas of environmental, social and governance issues. We hope you have a chance to review our progress in ESG by checking out the report on the Agilent website learning more about how we're executing our mission to advance the quality of life.
Agilent's Q3 results again point to the strength of our diversified business and the outstanding execution ability of the Agilent team. We continue to bring innovative differentiated new offerings in the marketplace. Acceleration in digital orders growth continues as well as new customer acquisition. In addition, as we started 2022, we undertook a bold move to create a One Agilent Commercial Organization to further drive customer focus and growth. The strength in our portfolio and the continued strong execution by our One Agilent Commercial Organization make a powerful combination, and you see in the results we're delivering.
Customer satisfaction hit another all-time high this quarter. We continue to outgrow the market. As a result of our strong Q3 performance and continuing momentum, we're once again raising our full-year revenue and EPS guidance. Bob will share more of the specifics. It's an exciting time in Agilent with the best yet to come.
Thank you for being on the call today. And now I will hand the call off to Bob. Bob?